The Effects of Immunotherapy in the Nose

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and other environmental insults. About 20 % of the European population suffers from pollen allergies. Birch pollen allergic rhinitis is the most common allergic disease in the Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of pollen allergies may be reduced by understanding the molecular biology of the nasal barriers during allergic response. Our aim is to observe the effect of season and birch pollen immunotherapy on the molecular biology of nasal epithelium and the microbiome.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Helsinki University Central Hospital
• Collaborators: Finnish Institute of Occupational Health; Helsinki University; University of Helsinki

Criteria

Inclusion Criteria:

• allergic rhinoconjunctivitis of birch pollen OR healthy controls

Exclusion Criteria:

• smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring constant medication